TW201021851A - Total nutrition infusion solution - Google Patents

Total nutrition infusion solution Download PDF

Info

Publication number
TW201021851A
TW201021851A TW098134787A TW98134787A TW201021851A TW 201021851 A TW201021851 A TW 201021851A TW 098134787 A TW098134787 A TW 098134787A TW 98134787 A TW98134787 A TW 98134787A TW 201021851 A TW201021851 A TW 201021851A
Authority
TW
Taiwan
Prior art keywords
solution
vitamin
liter
comprehensive nutrient
acid
Prior art date
Application number
TW098134787A
Other languages
Chinese (zh)
Other versions
TWI474840B (en
Inventor
Toshiyuki Katsura
Daisuke Miyajima
Kazuhiro Abiko
Mutsuo Shigeta
Yukifumi Kokuba
Original Assignee
Ajinomoto Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ajinomoto Kk filed Critical Ajinomoto Kk
Publication of TW201021851A publication Critical patent/TW201021851A/en
Application granted granted Critical
Publication of TWI474840B publication Critical patent/TWI474840B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A61K31/714—Cobalamins, e.g. cyanocobalamin, i.e. vitamin B12
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/26—Cyanate or isocyanate esters; Thiocyanate or isothiocyanate esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A61K31/51—Thiamines, e.g. vitamin B1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

This is to provide a total nutrition infusion solution containing vitamins and micronutrient elements in a stable state for a long time. In a vessel having four rooms separated by partitions which are breakable to form a single room, solution A containing reducing sugar, vitamin B1 groups and vitamin B6, solution B containing amino acids, vitamin B2 and pantothenic acid group, solution C containing vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin H and iodine, and solution D containing iron and cupper are contained in each room to provide a total nutrition infusion solution.

Description

201021851 六、發明說明： 【發明所屬之技術領域】 本發明有關調配有還原糖（reducing sugar)、胺基酸 (amino acid ) '電解質、維生素（vitamin)以及微量元 素、並經加熱滅菌處理之綜合營養輸液劑。 【先前技術】 φ 近年來，經靜脈營養療法有了長足的進步，而普遍採 用含有糖·電解質•胺基酸之輸液劑。但，在不能實施口 服營養補給而僅依賴經靜脈營養輸液時，如僅投予糖•電 解質•胺基酸時，則會發生維生素或微量元素的缺乏症。 又，如不投予維生素B1之下施加大量的糖分負荷時，則 在糖分新陳代謝上會有很大的異常，而很可能引起嚴重的 副作用的一種之乳酸中毒（acidosis)。於是，在醫療現 場則藉由混合注射於糖·電解質•胺基酸輸液中按使用時 ❹ 之方式添加維生素製劑或微量元素製劑。但，混合注射時 因操作煩雜而有因下藥錯誤所引起之醫療過失的危險性。 又，恐有因混合注射之操作所引起之細菌污染或異物混入 之可能性，而可能成爲醫療事故之一因。於是，有人開發 一種含有還原糖、胺基酸、電解質以及維生素並且能在無 菌狀態下混合溶液之製劑。 例如，於專利文獻1或專利文獻2中，揭示調配有維 生素之輸液劑。 但，雖由於上述之在來技術而維生素類以穩定性可獲 -5- 201021851 提升’惟微量元素的含有方式係其課題所在，而盼望其改 良法之開發。例如’按不受氧氣的影響之方式在脫氧狀態 下保存輸液劑時’如將銅離子及碘離子收納於同一室內時 則會生成沉锻。作爲其對策，專利文獻3中揭示有將銅離 子及碘離子分開收納，而於胺基酸液及/或糖液中含有碘 離子之輸液劑。此種方法，係由於碘離子被收納於大容量 的室內之故’作成微量之碘的濃度變成更稀薄，以致恐有 含量的測定上發生困難之可能性。又，專利文獻4中揭示 ^ 有含有銅離子及碘離子之藥液被含有氧氣之氣體一起收納 於氣體阻障（gas barrier )性之輸液劑。此種方法，係由 於氧氣阻障性的材質爲高價，且爲與含有氧氣之氣體一起 收納之故，製造時的過程變成煩雜等而恐有成本上升的可 能性。 [先前技術文獻] 專利文獻1 :日本專利特開平1 1 - 1 5 8 06 1號公報 專利文獻2 :日本專利特開2〇〇1_5 53 28號公報 0 專利文獻3 :日本專利特開20〇3-16〇5〇1號公報 專利文獻4 ··日本專利特開2006_20657號公報 【發明內容】 [發明所欲解決之課題] 本發明，係提供—種含有還原糖、胺基酸、電解質、 維生素以及微量元素’且維生素類及微量元素能長期性穩 定的綜合營養輸液劑者。由於還原糖、胺基酸、電解質、 -6- 201021851 維生素以及微量元素的各成分，係由於能使其穩定的pH 範圍不相同，又有發生互相作用者之故，需要考慮後再設 定對各室之調配。特別是調配微量元素時，有需要抑制保 存時的無氧氣狀態下之碘的含量低落。再者，此時需要設 法作成爲品質管理之用的碘含量測定上不致於有困難之方 式。 0 [用於解決課題之手段] 本發明人等，經專心硏究之結果，發現一種在保持維 生素的穩定性之下，解除碘的含量低落現象並以簡易方式 使微量元素穩定化之方法。再者，採用此種方法時，碘含 量的測定亦會成爲容易。亦即，藉由銅與鐵等的微量元素 一起調配，碘與脂溶性維生素一起配調而避免銅離子與碘 離子之共存者。本發明，係關於下列綜合營養輸液劑者。 1. —種綜合營養輸液劑，其特徵爲：將溶液A、溶液 Ο B、溶液C以及溶液D收納於經以能連通之隔牆所隔開之 4室容器的各室中’溶液A含有還原糖及維生素B1類、 溶液B含有胺基酸、溶液C含有選自維生素A、維生素D 、維生素E、維生素K中之至少1種以上的脂溶性維生素 及碘，而溶液D含有銅。 2. —種綜合營養輸液劑，其特徵爲··將溶液A、溶液 B、溶液C以及溶液D收納於經以能連通之隔牆所隔開之 4室容器的各室中，溶液A含有還原糖及維生素B1類、 溶液B中含有胺基酸、溶液c含有選自維生素A、維生素 201021851 D、維生素E、維生素K中之至少1種以上的脂溶性維生 素及碘、溶液D含有鐵及銅，再者，溶液Α及/或溶液Β 及/或溶液C及/或溶液D含有電解質，並經加熱滅菌處理 〇 3. 如1或2所記載之綜合營養輸液劑，其中溶液C再 含有維生素C且不含有維生素B2。 4. 如1或2所記載之綜合營養輸液劑，其中溶液C含 有維生素A、維生素D、維生素E、維生素K、維生素C 、生物素（biotin) '及葉酸（folic acid )，且不含維生 素B2。 5. 如1至4之任一項所記載之綜合營養輸液劑，其中 溶液 C中的碘的濃度爲 O.lOmmol (毫莫耳）/公升至 0.25mmol/公升。 6. 如1至5之任一項所記載之綜合營養輸液劑，其中 溶液A中，再含有作爲磷之含磷酸胺二鉀之電解質，且含 有檸檬酸（citric acid )。 7. 如1至6之任一項所記載之綜合營養輸液劑，其中 溶液 A再含有維生素B6、維生素B12以及菸鹼酸（ nicotinic acid)類，溶液B再含有維生素B2及泛酸（ pantothenic acid )類，溶液C再含有維生素C、維生素Η 以及葉酸（folic acid)。 8. 如1至6之任一項所記載之綜合營養輸液劑，其中 溶液A中再含有維生素B6及維生素B12，溶液B再含有 維生素B2、泛酸類以及菸鹼酸類，而溶液C再含有維生 -8- 201021851 素c、維生素Η以及葉酸。 9. 如1至8之任一項所記載之綜合營養輸液劑，其中 溶液D再含有錳及鋅。 10. 如1至9之任一項所記載之綜合營養輸液劑，其 中電解質係選自鈉、鉀、鎂、鈣、氯（C1)、磷中之至少 1種以上。 11. 如1至10之任一項所記載之綜合營養輸液劑，其 參 中維生素Β1類係選自硫胺素（thiamine)、硫胺素二硫化 物（thiamine disulfide )、呋喃硫胺（fursultiamine )、 苯磷硫胺（benfotiamine)以及此等的鹽中之至少1種以 上。 12. 如1至11之任一項所記載之綜合營養輸液劑，其 中溶液A的pH爲3至6’溶液B、溶液C以及溶液D的 pH爲5至8’而混合有溶液a、溶液B、溶液C以及溶液 D之溶液的pH爲4.5至7.5。 ® 13.如1至12之任—項所記載之綜合營養輸液劑，其 中於混合有溶液A、溶液B、溶液C以及溶液〇時的成分 組成中，胺基酸濃度爲25g/公升至55g/公升。 14.如13所記載之綜合營養輸液劑，其中非蛋白卡路 里（calorie)與投予氮量的比値爲9〇至ι6〇。 [發明之效果] 本方法中’由於按不同室方式調配銅離子及碘離子之 故可防止在去氧氣狀態下的因銅離子及碘離子所引起之沉 -9- 201021851 澱。再者，由於小容量之溶液C的室內收納碘離子之故可 設定碘濃度爲高濃度，而有容易測定碘含量之優點。又， 由於不需要將藥液與氧氣含有氣體一起收納之故不需要使 用聚乙烯•乙烯基醇共聚物（EVOH )、聚氯化亞乙烯（ PVOC )等具高阻障性之材質，而可依通常的方法廉價方 式製造。由於碘離子與脂溶性維生素可穩定混在之故，不 會發生脂溶性維生素及碘的含量低落。 [發明之最佳實施形態] 以下，就本發明之綜合營養輸液劑加以詳細說明。 經將溶液A、溶液B、溶液C以及溶液D收納於以能 連通方式之隔牆所隔開之4室容器的各室之本發明之綜合 營養輸液劑，係在加熱滅菌時或保存時經適當調配於按各 成分能穩定存在之方式所隔離之各室之一方面，連通後， 基本上可按不致於使內容物曝露於外氣之方式在無菌狀態 下加以混合。 本發明之綜合營養輸液劑中之溶液A，係以還原糖及 維生素B1作爲基本組成，較佳爲不含有亞硫酸及其鹽。 可使用之糖而言，祗要是通常輸液劑所用之糖則並不特別 加以限制，惟可例舉：葡萄糖（glucose )、果糖（ fructose)、麥芽糖（maltose)。又，維生素 B1而言， 可舉：硫胺素、硫胺素二硫化物、呋喃硫胺（ fursultiamine)、苯憐硫胺（benfotiamine)以及此等的鹽 等，較佳爲鹽酸硫胺素（thiamin hydrochloride)。又， 201021851 較佳爲溶液A中再調配維生素B6及維生素B12。維生素 B6而言，可舉：吡哆素（pyridoxine )、吡哆醇（ pyridoxol)、吡哆胺（pyridoxamine)以及此等的鹽等， 其中較佳爲鹽酸吡哆素（pyridoxine hydrochloride )。維 生素B12中，例如，包含氰銘胺素（cyano cobalamine) 及其鹽。 溶液A的pH，較佳爲調整於3至6。 φ 溶液A，較佳爲再含有電解質。此時，作爲磷供給來 源，有時含有磷酸氫二鉀等的磷酸鹽及鈣鹽。此時，如作 爲pH調節劑而採用檸檬酸時，則由於能抑制磷酸鈣之生 成之故，從滅菌時及長期保存時中之製劑的穩定性提升的 觀點來看很合適。在提高溶液A的還原糖及電解質濃度之 情形或將pH作成5以上之情形，特佳爲採用檸檬酸。 溶液A的液量，作爲半日至1日投予用的製劑，較佳 爲 400 至 1400ml，特佳爲 400 至 1100ml。 Φ 溶液B，爲胺基酸液。胺基酸的調配比例，可作成與 在來的胺基酸液的調配比例相同。於本發明之綜合營養輸 液劑中，可使用之胺基酸而言，祗要是通常可用於輸液之 胺基酸則並不特別加以限制。具體可舉：L (左旋）-異亮 胺酸（L-isoleucine ) 、L-亮胺酸（L-leucine ) ' L-離胺酸 (L-lysine) 、L-甲硫胺酸（L-methionine) 、L-苯基丙胺 酸（L-phenylalanine)、蘇胺酸（L-threonine) 、L -色胺 酸（L-tryptophane ) 、L-纈胺酸（L-valine ) 、L-丙胺酸 (L-alanine ) 、L-精胺酸（L-arginine ) 、L-天門冬胺酸 -11 - 201021851 (L-asparaginic acid)、半眺胺酸（cysteine) 、L -谷胺 酸（L-glutaminic acid ) 、L-組胺酸（L-histidine ) '脯胺 酸（L-proline ) 、L-絲胺酸（L-serine ) 、L-酪胺酸（L- tyro sine )、對羥苯甘胺酸（glycine )等。胺基酸不僅係 游離的胺基酸而可爲其鹽。此種鹽而言，可例舉：L-離胺 酸醋酸鹽、L-離胺酸鹽酸鹽。再者，其一部分可爲醯基體 或肽（peptide)。此種醯體而言，可例舉：乙醯半胱胺酸 (acetylcysteine ) ° 溶液B中，爲胺基酸液的穩定化起見，可添加亞硫酸 鹽或亞硫酸氫鹽，例如，亞硫酸氫鈉。 又，溶液B中，較佳爲再調配維生素B2及泛酸類。 維生素B2而言，可舉：核黃素（riboflavine)、核黃素 碟酸酯及其鈉鹽、黃素單核苷酸（flavin mono nucleotide )，其中特佳爲核黃素磷酸鈉。泛酸類而言，可舉：泛酸 或其鈣鹽、泛酸醇（pantothenol )等，較佳爲泛酸醇。 溶液B的pH，較佳爲調整於5至8。 溶液B的液量，作爲半日至1日投予用的製劑，較佳 爲200至700ml，特佳爲300至600ml。 較佳爲對A液或B液，調配菸鹼酸（nicotinic acid) 類。菸鹼酸類而言，可舉··菸鹼酸、菸鹼醯胺、菸鹼酸鈉 、薛驗酸甲酯等，較佳爲薛驗酿胺。 溶液C含有選自維生素A、維生素D、維生素E、維 生素K之至少1種以上的脂溶性維生素，而需要時可添加 可溶化劑。 -12- 201021851 維生素A而言，可包含視黃醇（retinol )或其酯等， 具體可舉，棕櫚酸視黃醇酯（retinol palmitate)、醋酸視 黃醇酯（retinol acetate)等，其中較佳爲棕櫚酸視黃醇酯 。維生素 D而言，可舉：維生素 D2(麥角鈣化醇 (ergocalciferol))、維生素 D3 (膽耗化醇（chole calciferol))以及此等的活性型（activated type)，其中 較佳爲膽鈣化醇。維生素 E而言，可舉：生育酚（ φ tocopherol )及其酯，更具體可舉，醋酸生育酚酯、玻珀 酸生育酚酯，其中較佳爲醋酸生育酚酯。維生素K而言， 可舉：維生素K1 (植物甲苯醌（phytonadione))、維生素 K2 (甲萘滿酮（menatetralone))、維生素 K3 (甲萘醌 (mena dione))等，其中較佳爲植物甲苯醌。 可溶化劑而言，可舉：聚山梨酸酯（poly sorbate) 80 、山梨酸酯20、HCO (氫化蓖麻油）-60、聚乙二醇等。 又，作爲穩定化劑，而可添加：山梨糖醇（sorbitol )、 Ο 甘露糖醇（mannitol )、木糖醇（xylitol )、麥芽醇（ maltibol)等的糖醇（sugaralcohol)、或甘油（glycerin )° 如溶液C中添加碘，則可穩定維持碘。再者，令人驚 奇之事，係在溶液C內，因碘之存在而不會發生上述脂溶 性維生素的含量低落。又，溶液C中所含有之脂溶性維生 素，係由於調配時需要小容量的介質（medium)即足夠之 故，溶液C的室爲小容量者，因而可設定碘的濃度爲高濃 度。因此，從甲狀腺的功能維持等的觀點來看，可容易且 -13- 201021851 正確實施重要的碘濃度的測定。較佳爲溶液C中碘濃度（ 碘化物離子濃度）在0·027至1.3mmol /公升，特佳爲在 0.10至0.25mm〇l/公升。碘供給來源而言，可例舉：碘化 鉀、碘化鈉等，其中較佳爲碘化鉀。 溶液C’實質上不含有銅。因而，即使在脫氧狀態下 仍然不會發生碘的沉澱。 溶液C再含有維生素c且不含有維生素B2爲宜。維 生素而Η，可舉：抗壞血酸（ascorbic acid)、抗壞血酸 滅^ 鈉等，較佳爲抗壞血酸。在維生素B2的非存在下，上述 脂溶性維生素、碘、以及維生素C的混合物將特別穩定存 在。 溶液c再含有維生素HC生物素（biotin))或葉酸（ folic acid)爲宜。特別是，在溶液C含有維生素A、維生 素D、維生素E、維生素K、維生素C、維生素Η (生物 素）、以及葉酸，且不含有維生素Β2的情形，溶液C中 的此等成分的穩定性特高。 參 溶液C的pH，較佳爲調整於5至8。 溶液C的液量，作爲半日至1日投予用的製劑，較佳 爲1至10rrU，特佳爲2至8ml。 溶液D，含有銅，較佳爲含有鐵、銅的微量元素。除 鐵、銅之外，尙含有錳、鋅等的微量元素爲宜。 鐵供給來源而言，可舉：硫酸鐵、氧化第一鐵、三氯 化鐵以及葡萄糖酸鐵。銅供給來源而言，可舉：硫酸銅等 。錳供給來源而言，可舉：氯化錳、硫酸錳等。鋅供給來 -14- 201021851 源而言，可舉：硫酸鋅、氯化鋅、葡萄糖酸鋅、乳酸鋅、 醋酸鋅等。 又’彳谷液D中’需要時亦可添加軟骨素（chondroitin )硫酸鈉。 溶液D的pH’較佳爲調整爲5至8。 溶液D的液量，作爲半日至i日投予用的製劑，較佳 爲1至10ml，特佳爲2至8ml。 〇 本發明之綜合營養輸液劑含有電解質。電解質祗要是 通常的電解質輸液等所用者，則並不特別加以限制，而可 舉：鈉、鉀、鈣、鎂、磷、氯等，較佳爲能在水溶液中生 成離子之無機鹽、有機鹽等。電解質，可含有於溶液A至 D的任一中，較佳爲溶液A中所含有。在此，電解質，係 爲維持生物體的功能或體液的電解質平衡（balance)上需 要者。 各溶液中所使用之pH調節劑而言，祗要是生理上能 ® 容許者則並不特別加以限定，例如可使用：有機酸、無機 酸、有機鹼、無機鹼。前述有機酸而言，可舉：醋酸、檸 檬酸、乳酸、琥珀酸' 蘋果酸（malic acid)等，無機酸 而言，可舉：鹽酸、硫酸、磷酸等。另一方面，有機鹼而 言，可舉：醋酸鈉、檸檬酸鈉、乳酸鈉，而無機鹼而言， 可舉：氫氧化鹼金屬（例如氫氧化鈉）等。201021851 VI. Description of the invention: [Technical field to which the invention pertains] The present invention relates to a combination of reducing sugar, amino acid 'electrolyte, vitamin and trace elements, and heat sterilization treatment Nutritional infusion. [Prior Art] φ In recent years, intravenous nutrition therapy has made great progress, and an infusion containing a sugar, electrolyte, and amino acid is generally used. However, when oral nutrition supplementation is not possible and oral vegetative infusion is relied on, if only sugar, electrolyte, and amino acid are administered, vitamin or trace element deficiency may occur. Further, if a large amount of sugar load is applied under the vitamin B1, there is a large abnormality in the metabolism of the sugar, and it is a kind of acidosis which is likely to cause serious side effects. Therefore, in the medical field, a vitamin preparation or a trace element preparation is added by mixing injection into a sugar/electrolyte/amino acid infusion solution as it is used. However, there is a risk of medical negligence caused by a mistake in the medicine due to troublesome operation during mixed injection. Further, there is a possibility that bacterial contamination or foreign matter may be mixed due to the operation of the mixed injection, and it may become a cause of medical accident. Thus, a formulation containing a reducing sugar, an amino acid, an electrolyte, and a vitamin and capable of mixing a solution in a sterile state has been developed. For example, in Patent Document 1 or Patent Document 2, an infusion solution prepared with vitamins is disclosed. However, due to the above-mentioned technology, the stability of vitamins can be improved by -5 - 201021851, but the way in which trace elements are contained is the subject of the problem, and we hope to improve the development of the method. For example, when the infusion solution is stored in a deoxidized state so as not to be affected by oxygen, when the copper ions and the iodide ions are accommodated in the same chamber, the forging is generated. As a countermeasure against this, Patent Document 3 discloses an infusion solution containing iodine ions in an amino acid solution and/or a sugar liquid, in which copper ions and iodide ions are separately stored. In this method, since the amount of iodine produced in a large-capacity room is reduced, the concentration of iodine is made thinner, so that it is difficult to measure the content. Further, Patent Document 4 discloses that a chemical solution containing copper ions and iodide ions is contained in a gas barrier infusion agent together with a gas containing oxygen. In this method, the material having an oxygen barrier property is expensive, and it is stored together with a gas containing oxygen, and the process at the time of manufacture becomes complicated, and there is a possibility that the cost increases. [Prior Art Document] Patent Document 1: Japanese Patent Laid-Open No. Hei 1 1 - 1 5 8 06 1 Patent Document 2: Japanese Patent Laid-Open No. Hei 2 _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ _ Japanese Laid-Open Patent Publication No. 2006-20657. SUMMARY OF THE INVENTION [Problems to be Solved by the Invention] The present invention provides a reducing sugar, an amino acid, an electrolyte, and the like. Vitamins and trace elements 'and vitamins and trace elements can be long-term stable comprehensive nutritional infusion agents. Because the reducing sugar, amino acid, electrolyte, -6-201021851 vitamins and trace elements are different because they can stabilize the pH range, and there are interactions, you need to consider Room deployment. In particular, when a trace element is formulated, it is necessary to suppress the low content of iodine in an oxygen-free state at the time of storage. Furthermore, at this time, it is necessary to set a method for measuring the iodine content for quality management without difficulty. [Means for Solving the Problem] As a result of intensive research, the present inventors have found a method for stabilizing the amount of iodine while maintaining the stability of vitamins and stabilizing the trace elements in a simple manner. Further, when such a method is employed, the measurement of the iodine content becomes easy. That is, by blending a trace element such as copper with iron, iodine is coordinated with a fat-soluble vitamin to avoid coexistence of copper ions and iodine ions. The present invention relates to the following comprehensive nutritional infusion agents. 1. A comprehensive nutrient infusion agent, characterized in that: solution A, solution Ο B, solution C and solution D are contained in each chamber of a 4-chamber container separated by a partition wall that can be connected. The reducing sugar and the vitamin B1 are contained, the solution B contains an amino acid, and the solution C contains at least one selected from the group consisting of vitamin A, vitamin D, vitamin E, and vitamin K, and iodine, and the solution D contains copper. 2. A comprehensive nutrient infusion agent characterized in that: solution A, solution B, solution C and solution D are contained in each chamber of a 4-chamber container separated by a partition wall, and solution A contains Reducing sugar and vitamin B1, solution B containing amino acid, solution c containing at least one selected from the group consisting of vitamin A, vitamin 201021851 D, vitamin E, vitamin K, fat-soluble vitamins and iodine, solution D containing iron and Copper, in addition, the solution Α and / or the solution Β and / or the solution C and / or the solution D contains the electrolyte and is sterilized by heat 〇 3. The comprehensive nutrient infusion agent as described in 1 or 2, wherein the solution C is further contained Vitamin C does not contain vitamin B2. 4. The comprehensive nutrient infusion solution according to 1 or 2, wherein the solution C contains vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, biotin' and folic acid, and does not contain vitamins. B2. 5. The comprehensive nutrient infusion solution according to any one of 1 to 4, wherein the concentration of iodine in the solution C is from 0.1 mol/m to 0.25 mmol/liter. 6. The comprehensive nutrient infusion solution according to any one of 1 to 5, wherein the solution A further contains an electrolyte containing phosphorus dipotassium phosphate as phosphorus, and contains citric acid. 7. The comprehensive nutrient infusion solution according to any one of 1 to 6, wherein the solution A further contains vitamin B6, vitamin B12 and nicotinic acid, and the solution B further contains vitamin B2 and pantothenic acid. Class C, solution C further contains vitamin C, vitamin strontium and folic acid. 8. The comprehensive nutrient infusion solution according to any one of 1 to 6, wherein the solution A further contains vitamin B6 and vitamin B12, and the solution B further contains vitamin B2, pantothenic acid and nicotinic acid, and the solution C further contains a dimension. Health-8- 201021851 Prime c, vitamins and folic acid. 9. The comprehensive nutrient infusion solution according to any one of 1 to 8, wherein the solution D further contains manganese and zinc. 10. The comprehensive nutrient infusion solution according to any one of 1 to 9, wherein the electrolyte is at least one selected from the group consisting of sodium, potassium, magnesium, calcium, chlorine (C1), and phosphorus. 11. The comprehensive nutrient infusion solution according to any one of 1 to 10, wherein the ginseng steroid 1 is selected from the group consisting of thiamine, thiamine disulfide, furfuramide (fursultiamine). And at least one or more of benfotiamine and such a salt. 12. The comprehensive nutrient infusion solution according to any one of 1 to 11, wherein the solution A has a pH of 3 to 6', and the solution B and the solution D have a pH of 5 to 8' mixed with the solution a and the solution. The pH of the solution of B, solution C and solution D is 4.5 to 7.5. ® 13. The comprehensive nutrient infusion solution as described in the items 1 to 12, wherein the amino acid concentration is 25 g/liter to 55 g in the composition of the solution A, solution B, solution C and solution. /liter. 14. The comprehensive nutrient infusion solution according to 13, wherein the ratio of non-protein calorie to the amount of nitrogen administered is from 9 to ι 6 〇. [Effect of the Invention] In the present method, since copper ions and iodide ions are formulated in different chamber manners, precipitation due to copper ions and iodide ions in the deoxygenation state can be prevented. Further, since the small-capacity solution C contains iodide ions in the room, the iodine concentration can be set to a high concentration, and the iodine content can be easily measured. Moreover, since it is not necessary to store the chemical liquid together with the gas containing oxygen, it is not necessary to use a material having high barrier properties such as polyethylene vinyl alcohol copolymer (EVOH) or polyvinyl chloride (PVOC). It is manufactured in a cheap manner according to the usual method. Since the iodide ion and the fat-soluble vitamin can be stably mixed, the fat-soluble vitamin and iodine content are not lowered. BEST MODE FOR CARRYING OUT THE INVENTION Hereinafter, the comprehensive nutrient infusion agent of the present invention will be described in detail. The integrated nutrient infusion solution of the present invention in which the solution A, the solution B, the solution C and the solution D are housed in the chambers of the 4-chamber container separated by the partition wall capable of being connected, is heated or sterilized or stored Appropriately formulated in one of the chambers isolated in such a manner that the components can be stably present, after being connected, it can be substantially aseptically mixed in such a manner that the contents are not exposed to the outside air. The solution A in the comprehensive nutrient infusion solution of the present invention has a reducing sugar and a vitamin B1 as a basic component, and preferably does not contain sulfurous acid and a salt thereof. As the sugar to be used, the sugar used in the usual infusion solution is not particularly limited, and examples thereof include glucose, fructose, and maltose. Further, as the vitamin B1, thiamine, thiamine disulfide, fursultiamine, benfotiamine, and the like may be mentioned, and thiamine hydrochloride is preferred. Thiamin hydrochloride). Further, 201021851 is preferably formulated with vitamin B6 and vitamin B12 in solution A. The vitamin B6 may, for example, be pyridoxine, pyridoxol, pyridoxamine or the like, and among them, pyridoxine hydrochloride is preferred. The vitamin B12 contains, for example, cyano cobalamine and a salt thereof. The pH of the solution A is preferably adjusted to 3 to 6. The φ solution A preferably further contains an electrolyte. In this case, as a phosphorus supply source, a phosphate or a calcium salt such as dipotassium hydrogen phosphate may be contained. In this case, when citric acid is used as the pH adjuster, since the production of calcium phosphate can be suppressed, it is suitable from the viewpoint of improving the stability of the preparation during sterilization and during long-term storage. In the case where the reducing sugar and the electrolyte concentration of the solution A are increased or the pH is made 5 or more, citric acid is particularly preferably used. The liquid amount of the solution A is preferably from 400 to 1400 ml, particularly preferably from 400 to 1100 ml, as a preparation for administration from half a day to one day. Φ Solution B is an amino acid solution. The blending ratio of the amino acid can be made to be the same as that of the existing amino acid. In the case of the amino acid which can be used in the comprehensive nutrient infusion of the present invention, the amino acid which is usually used for infusion is not particularly limited. Specifically, L (left-handed)-isoleucine (L-isoleucine), L-leucine (L-leucine), L-lysine, L-methionine (L- Methionine), L-phenylalanine, L-threonine, L-tryptophane, L-valine, L-alanine (L-alanine), L-arginine, L-aspartate-11 - 201021851 (L-asparaginic acid), cysteine, L-glutamine (L- Glutaminic acid ), L-histidine 'L-proline', L-serine, L-tyro sine, p-hydroxybenzene Glycine (glycine) and the like. The amino acid is not only a free amino acid but also a salt thereof. The salt may, for example, be L-isoamine acid acetate or L-isoamine hydrochloride. Further, a part thereof may be a ruthenium matrix or a peptide. In the case of such a steroid, acetylcysteine can be exemplified. In the solution B, for the stabilization of the amino acid solution, a sulfite or a bisulfite can be added, for example, Sodium hydrogen sulfate. Further, in the solution B, it is preferred to reconstitute vitamin B2 and pantothenic acid. The vitamin B2 includes riboflavine, riboflavin acid ester and its sodium salt, and flavin mononucleotide, of which riboflavin sodium phosphate is particularly preferred. The pantothenic acid may, for example, be pantothenic acid or a calcium salt thereof, pantothenol or the like, and is preferably pantothenic acid. The pH of solution B is preferably adjusted to 5 to 8. The liquid amount of the solution B is preferably from 200 to 700 ml, particularly preferably from 300 to 600 ml, as a preparation for administration from half a day to one day. Preferably, for the liquid A or the liquid B, a nicotinic acid is formulated. The nicotinic acid may, for example, be nicotinic acid, nicotinamide, sodium nicotinate or methyl primate, and is preferably Schulcan. The solution C contains at least one type of fat-soluble vitamin selected from the group consisting of vitamin A, vitamin D, vitamin E, and vitamin K, and a solubilizing agent may be added as needed. -12- 201021851 Vitamin A may include retinol or its ester, and specifically, retinol palmitate, retinol acetate, etc. Preferred is retinyl palmitate. The vitamin D may, for example, be vitamin D2 (ergocalciferol), vitamin D3 (chole calciferol), and the activated type thereof, among which cholecalciferol is preferred. . The vitamin E is exemplified by tocopherol (φ tocopherol) and its ester, and more specifically, tocopheryl acetate and tocopheryl peroxide, among which tocopheryl acetate is preferred. The vitamin K is exemplified by vitamin K1 (phytonadione), vitamin K2 (menatetralone), vitamin K3 (mena dione), and the like, among which plant toluene is preferred. Hey. The solubilizing agent may, for example, be polysorbate 80, sorbate 20, HCO (hydrogenated castor oil)-60 or polyethylene glycol. Further, as a stabilizing agent, sugar alcohol (sugaralcohol) such as sorbitol, mannitol, xylitol, maltibol, or glycerin may be added (or glycerol). Glycerin )° If iodine is added to solution C, iodine can be stably maintained. Further, it is surprising that in the solution C, the above-mentioned fat-soluble vitamin is not lowered due to the presence of iodine. Further, the fat-soluble vitamin contained in the solution C is sufficient because a medium having a small capacity is required for preparation, and the chamber of the solution C has a small capacity. Therefore, the concentration of iodine can be set to a high concentration. Therefore, from the viewpoint of maintaining the function of the thyroid gland, etc., it is possible to easily perform the measurement of the important iodine concentration with ease and from -13 to 201021851. Preferably, the iodine concentration (iodide ion concentration) in the solution C is from 0.027 to 1.3 mmol / liter, particularly preferably from 0.10 to 0.25 mm liter / liter. The source of iodine supply may, for example, be potassium iodide or sodium iodide, and among them, potassium iodide is preferred. Solution C' does not substantially contain copper. Thus, precipitation of iodine does not occur even in the deoxidized state. Solution C further contains vitamin C and does not contain vitamin B2. The vitamins may be mentioned as: ascorbic acid, ascorbic acid, sodium, etc., preferably ascorbic acid. In the absence of vitamin B2, the above mixture of fat-soluble vitamins, iodine, and vitamin C will be particularly stable. Solution c further contains vitamin HC biotin or folic acid. In particular, in the case where solution C contains vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin Η (biotin), and folic acid, and does not contain vitamin Β 2, the stability of these components in solution C Extra high. The pH of the reference solution C is preferably adjusted to 5 to 8. The liquid amount of the solution C is preferably from 1 to 10 rrU, particularly preferably from 2 to 8 ml, as a preparation for administration from half a day to one day. Solution D contains copper, preferably a trace element containing iron or copper. In addition to iron and copper, strontium contains trace elements such as manganese and zinc. As the source of iron supply, iron sulfate, first iron oxide, iron trichloride, and iron gluconate can be mentioned. As the source of copper supply, copper sulfate or the like can be mentioned. Examples of the source of manganese supply include manganese chloride and manganese sulfate. Zinc supply -14- 201021851 Source: zinc sulfate, zinc chloride, zinc gluconate, zinc lactate, zinc acetate, etc. Further, chondroitin sodium sulfate may be added as needed. The pH' of the solution D is preferably adjusted to 5 to 8. The liquid amount of the solution D is preferably from 1 to 10 ml, particularly preferably from 2 to 8 ml, as a preparation for administration from half a day to i day.综合 The integrated nutrient infusion agent of the present invention contains an electrolyte. The electrolyte is not particularly limited as long as it is used for ordinary electrolyte infusion, and the like: sodium, potassium, calcium, magnesium, phosphorus, chlorine, etc., preferably inorganic salts and organic salts capable of generating ions in an aqueous solution. Wait. The electrolyte may be contained in any of the solutions A to D, preferably in the solution A. Here, the electrolyte is required to maintain the function of the living body or the electrolyte balance of the body fluid. The pH adjuster used in each solution is not particularly limited as long as it is physiologically acceptable. For example, an organic acid, an inorganic acid, an organic base or an inorganic base can be used. Examples of the organic acid include acetic acid, citric acid, lactic acid, and succinic acid 'malic acid. The inorganic acid may, for example, be hydrochloric acid, sulfuric acid or phosphoric acid. On the other hand, the organic base may, for example, be sodium acetate, sodium citrate or sodium lactate, and the inorganic base may, for example, be an alkali metal hydroxide (for example, sodium hydroxide).

中心靜脈（central vein )用輸液，作爲1日投予量， 在抑制總水分量爲1400至1 800ml之下，將胺基酸作成 45至75g，將非蛋白卡路里與投予氮氣量的比例（NPC/N -15- 201021851 比）作成9〇至160的範圍爲宜（日本專利特開2008-26628 8號公報），而本發明之綜合營養輸液劑，較佳爲具 有能提供此種輸液合適的還原糖及胺基酸濃度。本發明之 綜合輸液製劑，可使用於消化器系統或循環器系統在手術 後的病痛侵襲（invasion )時的病患，再者，亦可使用於 吞嚥不能（aphagia)或腦梗塞後遺症等、經口、經管營養 攝取不能或不充分且能量需求量低落之病患，例如高齡者 等。 又，本發明之綜合輸液製劑所含之維生素類，係能確 保美國醫師會所推薦之維生素需要量之維生素濃度者爲宜 。例如’維生素B1 (硫胺素）6.0mg (微克）/日、維生素 C 200mg/日。 於本發明之綜合營養輸液劑中，於混合有溶液A、溶 液B、溶液C以及溶液D之溶液的成分組成中，較佳爲如 下所述：作成 葡萄糖爲50至400g/公升、更佳爲1〇〇至25〇g/公升 〇 作爲胺基酸總量爲25.0至55.〇g /公升。 (各胺基酸（換算爲游離體）） L-異亮胺酸爲0.2至l4.〇g/公升、更佳爲1〇至6川… 公升、 L-亮胺酸爲0.4至20.0g/公升、更佳爲1 〇至i〇 〇g/ 公升、 201021851 L-離胺酸爲0.2至14.0g/公升、更佳爲1.0至5.Og/公 升、 L-甲硫胺酸爲0.1至8.Og/公升、更佳爲0.5至5.Og/ 公升、 L-苯基丙胺酸爲0.2至12.Og/公升、更佳爲1.0至 5.0g/公升、 L-蘇胺酸爲0.1至8.0g/公升、更佳爲0.5至4.0g/公 參 升、 L-色胺酸爲0.04至3.0g/公升、更佳爲0.2至1 .5 g/公 升、 L-纈胺酸爲0.1至16.0g/公升、更佳爲1.0至6.0g/公 升、 L-丙胺酸爲0.2至14.0g/公升、更佳爲1.0至6.0g/公 升、 L-精胺酸爲0.2至14.0g/公升、更佳爲1·〇至7.0g/公 ❿升、 L-天門冬胺酸爲0.01至4.0g/公升、更佳爲0.1至 2.0g/公升、 L-谷胺酸爲0.01至6.0g/公升、更佳爲0.1至2.0g/公 升、 L-組胺酸爲0.1至8.0g/公升、更佳爲〇_5至5.0g/公 升、 L-脯胺酸爲0.1至10.0g/公升、更佳爲0.5至5.0g/公 升、 -17- 201021851 L-絲胺酸爲〇·〗至6_0g/公升、更佳爲〇 2至3 〇g/公 升 L-酪胺酸爲〇·〇1至2.0g/公升、更佳爲〇 〇5至1〇 公升、 對羥苯甘胺酸爲〇·1至12.0e//A 歼、更佳爲1.0 g/ 5.0g/公升、 L-半胱胺酸爲0.01至2.〇g/公# 公升。 楚佳爲0.1至2.〇 8/ (維生素類） 維生素A爲500至sOOOIUCig^ 陶嚓單位）/公升、更& 爲1000至4000IU/公升； 更隹 0至20pg (微克）/ 1 · 〇至3 Omg (毫克） 0-1 至 5.0mg/公升、The central vein is infused as a one-day dose. Under the total water content of 1400 to 1 800 ml, the amino acid is 45 to 75 g, and the ratio of non-protein calories to the amount of nitrogen administered is The NPC/N -15-201021851 ratio is preferably in the range of 9 to 160 (Japanese Patent Laid-Open No. 2008-26628 No. 8), and the integrated nutrient infusion agent of the present invention preferably has a suitable infusion solution. Reducing sugar and amino acid concentration. The integrated infusion preparation of the present invention can be used for a patient in a gastrointestinal system or a circulator system after invasive surgery, and can also be used for aphagia or sequelae of cerebral infarction. Patients whose oral and oral nutritional intake is insufficient or insufficient and whose energy demand is low, such as elderly people. Further, the vitamins contained in the integrated infusion preparation of the present invention are preferably those which can ensure the vitamin concentration of the vitamin requirement recommended by the American College of Physicians. For example, 'vitamin B1 (thiamine) 6.0 mg (microgram) / day, vitamin C 200 mg / day. In the comprehensive nutrient infusion solution of the present invention, in the composition of the solution in which the solution A, the solution B, the solution C and the solution D are mixed, it is preferably as follows: the glucose is 50 to 400 g/liter, more preferably The total amount of 1 〇〇 to 25 〇 g / liter as the amino acid is 25.0 to 55. 〇 g / liter. (each amino acid (in terms of free form)) L-isoleucine is 0.2 to 14. 〇g / liter, more preferably 1 〇 to 6 liters, liters of L-leucine is 0.4 to 20.0 g / Liters, more preferably 1 〇 to i〇〇g / liter, 201021851 L-isoaminic acid is 0.2 to 14.0 g / liter, more preferably 1.0 to 5. Og / liter, L-methionine is 0.1 to 8 .Og/liter, more preferably 0.5 to 5.Og/liter, L-phenylalanine is 0.2 to 12.Og/liter, more preferably 1.0 to 5.0 g/liter, and L-threonine is 0.1 to 8.0. g/liter, more preferably 0.5 to 4.0 g / ginseng, L-tryptophan 0.04 to 3.0 g / liter, more preferably 0.2 to 1.5 g / liter, L-proline is 0.1 to 16.0 g/liter, more preferably 1.0 to 6.0 g/liter, L-alanine is 0.2 to 14.0 g/liter, more preferably 1.0 to 6.0 g/liter, and L-arginine is 0.2 to 14.0 g/liter, more Preferably, it is from 1.0 to 7.0 g/liter, L-aspartic acid is from 0.01 to 4.0 g/liter, more preferably from 0.1 to 2.0 g/liter, and L-glutamic acid is from 0.01 to 6.0 g/liter. More preferably, it is 0.1 to 2.0 g/liter, L-histamine is 0.1 to 8.0 g/liter, more preferably 〇5 to 5.0 g/liter, and L-proline is 0.1 to 10.0 g/liter, more preferably 0.5 to 5.0g/liter, -17- 201021851 L-serine is 〇·〗 to 6_0g/liter, more preferably 至2 to 3 〇g/liter L-tyrosine is 〇·〇1 to 2.0g/liter, More preferably, it is 5 to 1 liter liter, p-hydroxyphenylglycine is 〇·1 to 12.0 e//A 歼, more preferably 1.0 g/5.0 g/liter, and L-cysteine is 0.01 to 2 .〇g/公# liters. Chu Jia is 0.1 to 2. 〇 8 / (vitamins) Vitamin A is 500 to sOOOOIUCig ^ pottery unit) / liter, more & 1000 to 4000 IU / liter; more 隹 0 to 20pg (microgram) / 1 · 〇 To 3 Omg (mg) 0-1 to 5.0 mg / liter,

維生素D (以膽骨化醇計）爲^ 公升、更佳爲ι·〇至i〇pg/公升、 維生素E (以醋酸生育酚計）馬 /公升、更佳爲2.0至Umg/公升、 維生素K (以植物甲萘醌計）馬 更佳爲0.2至2.5mg/公升、 維生素B1 (以鹽酸硫胺素計） 更佳爲1_〇至20mg/公升' 、、' 0·5至50mg/公升、 維生素B2(以核黃素計） 爲"至5.〇mg/公升、 ‘、、〇·4 _公升、更佳 馬0.5至10mg/公升、 維生素Β ό (以鹽酸吡哆素計 更佳爲1.0至5.〇mg/公升、 >18- 201021851 維生素B12(以氰鈷胺素計）爲1〇至2〇|^/公升、 更佳爲1.0至10pg /公升、 兹驗酸類（以薛驗醯胺計）爲5.0至8 0mg/公升、更 佳爲1 0至5 0 m g_/公升、 維生素C (以抗壞血酸計）爲25至3 00m g/公升、更 佳爲25至200mg/公升、 泛酸類（以泛酸醇計）爲10至3〇mg/公升、更佳爲 ❿ 1.0至20mg/公升、 葉酸爲50至500Mg/公升、更佳爲1〇〇至4〇〇^g/公升 維生素Η (生物素）爲10至2〇〇μ§/公升更佳爲1〇 至1 00 pg/公升。 (微量元素） 鐵爲5.至ΙΟΟμιηοΙ /公升、 Φ 銅爲1至20μηιο1/公升、 錳爲0.1至5μιηο1/公升、 鋅爲5至1 50μιηο1/公升、 碘爲0.1至5μπιο1/公升。 (電解質） 鈉離子爲25至75mEq (毫當量）/公升 钟離子爲15至45mEq/公升、 錦離子爲2·5至10mEq/公升、 -19· 201021851 鎂離子爲2.5至10mEq/公升、 氯離子爲2.5至75mEq/公升、 磷爲0至20mmol/公升。 又，本發明之綜合營養輸液劑中，混合有溶液A、溶 液B、溶液C以及溶液D之溶液的PH，較佳爲作成能成 爲4.5至7.5之方式。 經以能連通之隔牆所隔開之4室容器而言，可使用周 知的容器。此中隔牆，係經以易剝離密封所構成之輸液袋 @ ，爲由於連通作業簡單之故較合適。輸液袋的素材，例如 聚乙烯、聚丙烯、聚丁烯般的聚烯烴、乙烯•丙烯共聚物 、交聯乙烯•醋酸乙烯共聚物，此等的層合物等較適當。 溶液C的容器材質，係能抑制脂溶性維生素的吸附之 材質爲宜，可例舉：環狀聚烯烴、聚對苯二甲酸乙二醇酯 、聚丙烯腈等。又，容器的表面積較小者爲宜。再者，作 爲層合物，亦可將與溶液C相接觸之最內層作成此等材質 ❹ 又，從防止溶液D的微量元素，與由溶液B的含硫胺 基酸所生成之氣體起反應而發生含量降低的觀點來看，作 爲溶液D的容器材質，採用氣體難穿透性的材質較宜。可 例舉：環狀烯烴、聚對苯二甲酸乙二醇酯、聚丙烯腈等。 再者，如溶液C與溶液D爲相同材質’則有可簡化製造過 程之優點。 塡充有藥液之容器，依常法與脫氧劑一起封入於具有 遮光性之由氣體非穿透性薄膜所成之外包裝材料中爲宜。 -20- 201021851 具有遮光性之氣體穿透性的外包裝材料而言，可舉：一般 泛用之鋁箔、鋁蒸鍍薄膜等。又，亦能組合具有遮光性之 層與具有氣體非穿透性之層之作法，而具有遮光性之層而 言，祗要是能通過作爲遮光性能所容許之穿透率者則並不 特別加以限定，惟例如可採用施加有黑色印刷之泛用樹脂 薄膜。又，氣體非穿透性的外包裝材料而言，能選擇：聚 對苯二甲酸乙二醇酯、聚萘二甲酸乙二醇酯、伸乙基•乙 φ 烯醇共聚物、聚氯化亞乙烯、聚丙烯腈、聚醯胺、鋁蒸鍍 薄膜、二氧化矽蒸鍍薄膜等，亦能以1種或組合數種之方 式使用。 脫氧劑而言，可採用：以氫氧化鐵、氧化鐵、碳化鐵 等的鐵化合物作爲主成分者。市售品而言，可舉：埃其列 斯（AGELESS )(三菱氣體化學社製）、莫裘蘭（ MOJULAN )(日本化藥社製）、色裘爾（SEAULE)(日 本曹達社製）等。 # 輸液袋與外包裝容器之間的空間，較佳爲經以氮氣等 惰性氣體所塡充者。 藉由此等方式，可在保存期間中，將包含各液之外包 裝材料內部作成脫氧狀態。 【實施方式】 [實施例] 其次，將舉出實施例以更詳細說明本發明內容’惟本 發明並不因此等實施例而有所限定。 -21 - 201021851 (實施例1 ) 將葡萄糖及電解質溶解於注射用水後，進行維生素 B1 (鹽酸硫胺素）、維生素B6(鹽酸吡哆素）、菸鹸醯 胺以及維生素B12(氰鈷胺素）等之溶解。經採用醋酸以 調節爲ρΗ4·5後，將全量作成500ml，並使用膜濾器（ membrane filter) ( 0·2μιη)加以過減，以調製表 1中所 示組成的溶液Α。 g 將各胺基酸溶解於注射用水後，進行維生素B2 (核 黃素磷酸鈉）及泛酸醇之溶解。對此溶液，作爲穩定化劑 而溶解亞硫酸氫鈉。經採用醋酸以調節爲PH6.5後，將全 量作成3 00ml，並使用膜濾器（0.2μπι )加以過濾，以調 製表1中所示組成的溶液Β。 使維生素Α (棕櫚酸視黃醇酯）、維生素D3(膽骨 化醇）、維生素E (醋酸生育酚）以及維生素Kl(植物甲 萘醌）藉由聚山梨酸酯20及聚山梨酸酯80而加以可溶化 @ 後，溶解於注射用水。再進行碘化鉀、山梨糖醇、維生素 C (抗壞血酸）、維生素Η (生物素）以及葉酸之溶解。 經採用氫氧化鈉以調節爲ΡΗ6.0後，將全量作成3ml後， 使用膜濾器（〇.2μπι)加以過濾，以調製表1中所示組成 的溶液C。 於經將軟骨素硫酸鈉溶解於注射用水之水溶液中，交 互添加經將三氯化鐵溶解於注射用水之水溶液與經將氫氧 化鈉溶解於注射用水之水溶液，以調製鐵膠質溶液。於此 -22- 201021851 溶液中’進行氯化锰、硫酸鋅、硫酸銅之溶解。經採用氫 氧化鈉以調節爲pH5_7後，將全量作成3ml後，使用膜濾 器（0·2μιη)加以過據’以調製表丨中所示組成的溶液D 〇 將溶液A、溶液B、溶液c以及溶液D分別塡充 5 00ml、3 00ml、3ml及3 ml於經以能連通之隔牆所隔開之 4室容器的各室’並進行空間部之氮氣取代後加以密封。 〇 依常法實施高壓蒸氣滅菌後，將製劑與脫氧劑（埃其列斯 、三菱氣體化學（股）製）一起封入於由氣體非穿透性薄 膜所成之外包裝材料中’製得本發明之綜合營養輸液劑。 溶液A、溶液B、溶液c以及溶液D的pH，分別爲約4.5 、6.5、6.0 以及 5.6。 在此’經組合溶液A至D之組成的pH，爲5.4。 (實施例2 ) Φ 按與實施例1同樣方式，調製表1中所示組成的溶液 A、溶液B、溶液C以及溶液D。將溶液a、溶液B、溶 液C以及溶液D分別塡充600ml、300ml、3ml、以及3ml 於經以能連通之隔牆所隔開之4室容器的各室，並進行空 間部之氮氣取代後加以密封。依常法實施高壓蒸氣滅菌後 ，將製劑與脫氧劑（埃其列斯、三菱氣體化學（股）製） 一起封入於由氣體非穿透性薄膜所成之外包裝材料中，製 得本發明之綜合營養輸液劑。溶液A、溶液B、溶液C以 及溶液D的pH，分別爲約4.5、6.5、6.0以及5.6。 -23- 201021851 (實施例3) 按與實施例1同樣方式，調製表1中所示組成的溶液 A、溶液B、溶液C以及溶液D。將溶液A的pH調節劑 ，則使用檸檬酸。將溶液A、溶液B、溶液C以及溶液D 分別塡充500ml、300ml、3ml以及3ml於經以能連通之隔 牆所隔開之4室容器的各室，並進行空間部之氮氣取代後 加以密封。依常法實施高壓蒸氣滅菌後，將製劑與脫氧劑 @ (埃其列斯、三菱氣體化學（股）製）一起封入於由氣體 非穿透性薄膜所成之外包裝材料中，製得本發明之綜合營 養輸液劑。溶液A、溶液B、溶液C以及溶液D的pH， 分別爲約4·5、6.5、6.0以及5.6。在此，經混合溶液A至 D之組成的pH，爲5.4。 (比較例1 ) 按與實施例1同樣方式，調製表1中所示組成的溶液 A、溶液B、溶液C以及溶液D。將溶液A、溶液B、溶 液C以及溶液D分別塡充500ml、300ml、3ml'以及3ml 於經以能連通之隔牆所隔開之4室容器的各室，並進行空 間部之氮氣取代後加以密封。依常法實施高壓蒸氣滅菌後 ，將製劑與脫氧劑（埃其列斯、三菱氣體化學（股）製） 一起封入於由氣體非穿透性薄膜所成之外包裝材料中，製 得比較例1的綜合營養輸液劑。溶液A、溶液B、溶液c 以及溶液D的pH，分別爲約4.5、6.5、6·0以及5.6。 • 24- 201021851 (試驗例1 ) 將上述實施例1及比較例1所調製之綜合營養輸液劑 在4〇°C 7 5%RH (相對濕度）中保存1個月後的微量元素含 量加以測定。將其結果，表示於表2中。在此，含量係以 對組成之百分比表示者。 由表2的結果可知，實施例1係較比較例1即使在40 G °C 75%RH中保存1個月後仍然微量元素的含量低落爲小， 且長期間穩定之事實。 又，將實施例1及比較例1所調製之綜合營養輸液劑 在40°C75%RH中保存1個月後的維生素類含量加以測定 。將其結果，表示於表3中。在此，含量係以對組成之百 分比表示者。 由表3的結果可知，實施例1係即使在40°C7 5%RH 中保存1個月後仍然維生素類的含量低落小，且本發明之 β 綜合營養輸液劑係維生素類在長期間穩定之事實。又，從 實施例1與比較例1的比較可知，溶液C中所含有之維生 素類（人、03、£、]<：1、（：、葉酸、生物素），係即使溶液 C中含有碘，仍然與不含有碘的情形一樣穩定者之事實。 (在此，溶液A、Β的組成，係實施例1與比較例1爲相 同者，而此等中所含有之維生素的穩定性上，在兩者之間 並無相差）。 (試驗例2 ) -25- 201021851 將實施例3所調製之綜合營養輸液劑在40°C75%RH 中保存1個月後的維生素含量加以測定。將其結果，表示 於表4中。在此，含量係以對組成之百分比表示者。雖然 菸驗醯胺並非含有於A溶液而係B溶液中所含有之處實施 例3爲與實施例1不相同者，惟實施例3中仍然與實施例 1同樣，溶液A、B、以及C中所含有之維生素類爲長期 間穩定者〃 再者，實施例1至3中的溶液C中的碘’如使用例如 經使用UV (紫光線）檢測器之HP LC (高效液相色譜）法 ’則可在不實施藥液的濃縮之下容易進行濃度之測定。 [產業上的利用可能性] 本發明可提供一種含有還原糖、胺基酸、電解質、維 生素以及微量元素，且維生素類及微量元素能在長期間穩 定的綜合營養輸液劑。 201021851 [表i]Vitamin D (calculated as biliary alcohol) is ^ liter, more preferably ι·〇 to i〇pg/liter, vitamin E (tocopherol acetate) horse/liter, more preferably 2.0 to Umg/liter, vitamin K (based on phytomenadione) is more preferably 0.2 to 2.5 mg / liter, vitamin B1 (based on thiamine hydrochloride), more preferably 1 to 20 to 20 mg / liter ',, ' 0 · 5 to 50 mg / Liters, vitamin B2 (in terms of riboflavin) is "to 5. 〇mg/L, ', 〇·4 _ liter, better horse 0.5 to 10 mg / liter, vitamin Β ό (based on pyridoxine hydrochloride More preferably 1.0 to 5. 〇 mg / liter, > 18 - 201021851 Vitamin B12 (calcium cyanocyanamine) is 1 〇 to 2 〇 | ^ / liter, more preferably 1.0 to 10pg / liter, (in terms of Xuezhengamine) is 5.0 to 80 mg / liter, more preferably 10 to 50 m g / liter, and vitamin C (ascorbic acid) is 25 to 300 m / liter, more preferably 25 to 200 mg / liter, pantothenic acid (based on pantothenic acid) is 10 to 3 mg / liter, more preferably ❿ 1.0 to 20 mg / liter, folic acid is 50 to 500 Mg / liter, more preferably 1 to 4 〇〇 ^ g/liter of vitamin Η (biotin) is 10 2〇〇μ§/liter is preferably 1〇 to 1 00 pg/liter. (trace element) iron is 5. to ΙΟΟμιηοΙ / liter, Φ copper is 1 to 20μηιο1/liter, manganese is 0.1 to 5μιηο1/liter, zinc 5 to 1 50 μm ηο 1 liter, iodine 0.1 to 5 μπιο 1 liter (electrolyte) sodium ion 25 to 75 mEq (milli eq) / liter of clock ion 15 to 45 mEq / liter, bromine ion 2 to 5 to 10 mEq / liter -19·201021851 Magnesium ion is 2.5 to 10 mEq/liter, chloride ion is 2.5 to 75 mEq/liter, and phosphorus is 0 to 20 mmol/liter. Further, the comprehensive nutrient infusion agent of the present invention is mixed with solution A, solution B, The pH of the solution of Solution C and Solution D is preferably such that it can be formed in a range of 4.5 to 7.5. A well-known container can be used for a 4-chamber container separated by a partition wall which can be connected. It is suitable for the infusion bag @ which is made of easy-to-peel seal. It is suitable for the connection operation. The materials of the infusion bag, such as polyethylene, polypropylene, polybutene-like polyolefin, ethylene/propylene copolymer, and Biethylene/vinyl acetate copolymer, such laminates The material of the container of the solution C is preferably a material capable of inhibiting the adsorption of fat-soluble vitamins, and examples thereof include a cyclic polyolefin, polyethylene terephthalate, polyacrylonitrile, and the like. A smaller surface area is preferred. Further, as the laminate, the innermost layer in contact with the solution C may be made of such a material, and the trace element from the solution D and the gas generated from the sulfur-containing amino acid of the solution B may be used. From the viewpoint of a decrease in the content of the reaction, it is preferable to use a material which is difficult to penetrate the gas as the material of the container of the solution D. The cyclic olefin, polyethylene terephthalate, polyacrylonitrile or the like can be exemplified. Further, if the solution C and the solution D are made of the same material, the advantage of the manufacturing process can be simplified. The container filled with the chemical liquid is preferably enclosed in a packaging material made of a gas non-penetrating film having a light-shielding property together with a deoxidizing agent according to a usual method. -20- 201021851 The outer surface of the gas-permeable outer packaging material is generally used in general aluminum foil or aluminum vapor-deposited film. Further, it is also possible to combine a light-shielding layer and a gas-impermeable layer, and the light-shielding layer is not particularly preferable because it can pass the transmittance as a light-shielding property. For example, a general-purpose resin film to which black printing is applied may be used. In addition, for gas non-penetrating packaging materials, polyethylene terephthalate, polyethylene naphthalate, ethylene ethyl phthalate copolymer, polychlorination The vinylidene, the polyacrylonitrile, the polyamine, the aluminum vapor-deposited film, the cerium oxide vapor-deposited film, etc. can also be used in one type or a combination of several types. As the deoxidizing agent, an iron compound such as iron hydroxide, iron oxide or iron carbide may be used as a main component. Commercially available items include: AEGESS (manufactured by Mitsubishi Gas Chemical Co., Ltd.), MOJULAN (manufactured by Nippon Kasei Co., Ltd.), and SEAULE (made by Japan Soda Co., Ltd.) Wait. # The space between the infusion bag and the outer packaging container is preferably filled with an inert gas such as nitrogen. By this means, the inside of the packaging material including the respective liquids can be deoxidized in the storage period. [Embodiment] [Embodiment] Next, the present invention will be described in more detail by way of examples, but the invention is not limited thereto. -21 - 201021851 (Example 1) After dissolving glucose and electrolyte in water for injection, vitamin B1 (thiamine hydrochloride), vitamin B6 (pyridinium hydrochloride), nicotinamide, and vitamin B12 (cyanocobalamin) were administered. ) and so on. After adjusting to ρ Η 4·5 with acetic acid, the whole amount was made into 500 ml, and the solution was adjusted by using a membrane filter (0·2 μm) to prepare a solution 组成 of the composition shown in Table 1. g After dissolving each amino acid in water for injection, the vitamin B2 (sodium riboflavin phosphate) and pantothenic acid are dissolved. For this solution, sodium hydrogen sulfite was dissolved as a stabilizer. After adjusting to pH 6.5 with acetic acid, the whole amount was made into 300 ml, and filtered using a membrane filter (0.2 μm) to adjust the solution enthalpy of the composition shown in Table 1. Vitamin Α (retinyl palmitate), vitamin D3 (cholecalciferol), vitamin E (tocopherol acetate) and vitamin K1 (phytomenadione) by polysorbate 20 and polysorbate 80 After being solubilized @, it is dissolved in water for injection. Further, potassium iodide, sorbitol, vitamin C (ascorbic acid), vitamin strontium (biotin), and folic acid are dissolved. After adjusting to ΡΗ6.0 with sodium hydroxide, the whole amount was made into 3 ml, and then filtered using a membrane filter (〇. 2 μm) to prepare a solution C of the composition shown in Table 1. The sodium chondroitin sulfate was dissolved in an aqueous solution of water for injection, and an aqueous solution in which ferric chloride was dissolved in water for injection and an aqueous solution in which sodium hydroxide was dissolved in water for injection were added to prepare an iron colloid solution. Here -22- 201021851 in the solution 'dissolution of manganese chloride, zinc sulfate, copper sulfate. After adjusting to pH 5_7 with sodium hydroxide, the whole amount was made into 3 ml, and then a membrane filter (0.2 μm) was used to prepare a solution D, a solution B, and a solution c according to the composition shown in the preparation table. And solution D was filled with 500 ml, 300 ml, 3 ml, and 3 ml, respectively, in each chamber of a 4-chamber container separated by a partition wall that can be connected, and sealed with nitrogen in the space portion, and then sealed. After the high-pressure steam sterilization is carried out according to the usual method, the preparation is sealed with a deoxidizer (made by Ethelis, Mitsubishi Gas Chemical Co., Ltd.) in a packaging material made of a gas non-penetrating film. The invention relates to a comprehensive nutrient infusion agent. The pH of Solution A, Solution B, Solution C, and Solution D were about 4.5, 6.5, 6.0, and 5.6, respectively. Here, the pH of the composition of the combined solutions A to D was 5.4. (Example 2) Φ In the same manner as in Example 1, Solution A, Solution B, Solution C, and Solution D having the compositions shown in Table 1 were prepared. Solution a, solution B, solution C, and solution D were respectively filled with 600 ml, 300 ml, 3 ml, and 3 ml in each chamber of a 4-chamber container separated by a partition wall capable of being connected, and subjected to nitrogen substitution in the space portion. Sealed. After the high-pressure steam sterilization is carried out according to the usual method, the preparation is sealed with a deoxidizing agent (made by Ethelis, Mitsubishi Gas Chemical Co., Ltd.) into a packaging material made of a gas non-penetrating film, and the present invention is obtained. The comprehensive nutrient infusion agent. The pH of Solution A, Solution B, Solution C, and Solution D were about 4.5, 6.5, 6.0, and 5.6, respectively. -23-201021851 (Example 3) In the same manner as in Example 1, Solution A, Solution B, Solution C, and Solution D of the compositions shown in Table 1 were prepared. To the pH adjuster of solution A, citric acid is used. Solution A, solution B, solution C, and solution D were respectively filled with 500 ml, 300 ml, 3 ml, and 3 ml in each chamber of a 4-chamber container separated by a separable partition wall, and subjected to nitrogen substitution in the space portion. seal. After the high-pressure steam sterilization is carried out according to the usual method, the preparation is sealed with a deoxidizer @ (Echelist, Mitsubishi Gas Chemical Co., Ltd.) in a packaging material made of a gas non-penetrating film. The invention relates to a comprehensive nutrient infusion agent. The pH of Solution A, Solution B, Solution C, and Solution D were about 4.5, 6.5, 6.0, and 5.6, respectively. Here, the pH of the composition of the mixed solutions A to D was 5.4. (Comparative Example 1) Solution A, Solution B, Solution C, and Solution D of the compositions shown in Table 1 were prepared in the same manner as in Example 1. Solution A, solution B, solution C, and solution D were respectively filled with 500 ml, 300 ml, 3 ml', and 3 ml in each chamber of a 4-chamber container separated by a partition wall capable of being connected, and subjected to nitrogen substitution in the space portion. Sealed. After high-pressure steam sterilization according to the usual method, the preparation is enclosed in a packaging material made of a gas non-penetrating film together with a deoxidizing agent (made by Ericsson, Mitsubishi Gas Chemical Co., Ltd.) to prepare a comparative example. 1 comprehensive nutrient infusion agent. The pH of Solution A, Solution B, Solution c, and Solution D were about 4.5, 6.5, 6.0, and 5.6, respectively. • 24-201021851 (Test Example 1) The content of trace elements after storage of the comprehensive nutrient infusion solution prepared in the above Example 1 and Comparative Example 1 at 4 ° C 75% RH (relative humidity) for 1 month was measured. . The results are shown in Table 2. Here, the content is expressed as a percentage of the composition. As is clear from the results of Table 2, Example 1 is a fact that the content of the trace element is small and stable over a long period of time even after storage for one month at 40 G °C and 75% RH. Further, the vitamin content of the comprehensive nutrient infusion solution prepared in Example 1 and Comparative Example 1 after storage for one month at 40 ° C in 75% RH was measured. The results are shown in Table 3. Here, the content is expressed as a percentage of the composition. As is clear from the results of Table 3, in Example 1, even after storage for one month at 40 ° C, 75% RH, the vitamin content was low, and the β-integrated nutrient infusion agent of the present invention was stable for a long period of time. fact. Further, from the comparison between Example 1 and Comparative Example 1, it is understood that the vitamins (human, 03, £, ] <: 1, (:, folic acid, biotin) contained in the solution C are contained in the solution C. The fact that iodine is still as stable as in the case of not containing iodine. (The composition of solution A and hydrazine is the same as in the case of Example 1 and Comparative Example 1, and the stability of the vitamin contained in these is There is no difference between the two. (Test Example 2) -25- 201021851 The vitamin content of the comprehensive nutrient infusion solution prepared in Example 3 after storage for one month at 40 ° C in 75% RH was measured. The results are shown in Table 4. Here, the content is expressed as a percentage of the composition. Although the smoke test is not contained in the A solution but is contained in the B solution, Example 3 is not the same as Example 1. In the same manner, in Example 3, as in Example 1, the vitamins contained in the solutions A, B, and C were stable for a long period of time. Further, the iodine in the solution C in Examples 1 to 3 For example, HP LC (High Performance Liquid Chromatography) using a UV (purple light) detector The concentration can be easily measured without concentration of the chemical solution. [Industrial Applicability] The present invention can provide a reducing sugar, an amino acid, an electrolyte, a vitamin, a trace element, and a vitamin and a trace amount. A comprehensive nutrient infusion that can stabilize the element for a long period of time. 201021851 [Table i]

成分 實施例1 實施例2 實施例3 比較例1 葡萄糖 125.0g 175.0g 125.0g 125.0g 氯化鈉 l_402g 1.402g 1.402g 1.402g 氯化鉀 0.417g 0.417g 0.417g 0.417g 氯化鈣 0.470g 0.470g 0.470g 0.470g 氯化鎂 0.407g 0.407g 0.407g 0.407g 甘油磷酸鉀(50%) 3.574g 3.574g - 3.574g 溶液A 磷酸氫二鉀 - - 1.254g - 乳酸鈉(50%) 3.586g 3.586g 3.586g 3.586g 鹽酸硫胺素(B1) 3.80mg 3.8mg 3.8mg 3.80mg 鹽酸毗哆素(B6) 3.60mg 3.60mg 2.50mg 3.60mg 菸鹼醯胺 20.00mg 20.00mg - 20.00mg 氰鈷胺素(B12) 2.5pg 2_5pg 5μβ 2.5μβ 全量 500mL 600mL 500mL 500mL L-精胺酸 3.150g 3.150g 3.150g 3.150g L-酪胺酸 0.150g 0.150g 0.150g 0.150g L-異亮胺酸 2.400g 2.400g 2.400g 2.400g L-亮胺酸 4.200g 4.200g 4.200g 4.200g L-甲硫胺酸 1.170g l-170g 1.170g 1.170g L-纈胺酸 2.400g 2.400g 2_400g 2.400g 醋酸L-離胺酸 4.440g 4.440g 4.440g 4.440g L-蘇胺酸 1.710g 1.710g 1.710g 1.710g L-丙胺酸 2.400g 2.400g 2.400g 2.400g L-天門冬胺酸 0.300g 0.300g 0.300g 0.300g L-谷胺酸 0.300g 0.300g 0.300g 0.300g 溶液B L-脯胺酸 1.500g l_500g l_500g 1.500g L-絲胺酸 0.900g 0.900g 0.900g 0.900g 對羥苯苷胺酸 1.77〇g 1.770g 1.770g 1.770g L-苯基丙胺酸 2.100g 2.100g 2.100g 2.100g L-組胺酸 1.500g 1.500g 1.500g 1.500g L-色胺酸 0.600g 0.600g 0.600g 0.600g 乙醯半胱胺酸 0.404g 0.404g 0.404g 0.404g 亞硫酸氫鈉 0.015g 0.015g 0.030g 0.015g 核黃素磷酸鈉(B2) 2.30mg 2.30mg 2.50mg 2.30mg 泛酸醇 7.00mg 7.00mg 7.50mg 7.00mg 菸鹼醯胺 - - 20.00mg - 全量 300mL 300mL 300mL 300mL 201021851Ingredient Example 1 Example 2 Example 3 Comparative Example 1 Glucose 125.0 g 175.0 g 125.0 g 125.0 g Sodium chloride 1-402 g 1.402 g 1.402 g 1.402 g Potassium chloride 0.417 g 0.417 g 0.417 g 0.417 g Calcium chloride 0.470 g 0.470 g 0.470g 0.470g Magnesium chloride 0.407g 0.407g 0.407g 0.407g Potassium glycophosphate (50%) 3.574g 3.574g - 3.574g Solution A Dipotassium hydrogen phosphate - - 1.254g - Sodium lactate (50%) 3.586g 3.586g 3.586g 3.586 g Thiamine hydrochloride (B1) 3.80mg 3.8mg 3.8mg 3.80mg Hydroquinone hydrochloride (B6) 3.60mg 3.60mg 2.50mg 3.60mg Nicotinamide 20.00mg 20.00mg - 20.00mg Cyanocobalamin (B12) 2.5 Pg 2_5pg 5μβ 2.5μβ Total 500mL 600mL 500mL 500mL L-arginine 3.150g 3.150g 3.150g 3.150g L-tyramine 0.150g 0.150g 0.150g 0.150g L-isoleucine 2.400g 2.400g 2.400g 2.400g L-leucine 4.200g 4.200g 4.200g 4.200g L-methionine 1.170g l-170g 1.170g 1.170g L-Proline 2.40g 2.400g 2_400g 2.400g L-Amino Acid 4.440g 4.440g 4.440g 4.440g L-threonine 1.710g 1.710g 1.710g 1.710g L-alanine 2.400g 2.400g 2.400g 2.400g L-Tianmen Amine acid 0.300g 0.300g 0.300g 0.300g L-glutamic acid 0.300g 0.300g 0.300g 0.300g Solution B L-proline acid 1.500g l_500g l_500g 1.500g L-serine 0.900g 0.900g 0.900g 0.900g Pair Hydroxyphenylglycine 1.77 g 1.770 g 1.770 g 1.770 g L-phenylalanine 2.100 g 2.100 g 2.100 g 2.100 g L-histamine 1.500 g 1.500 g 1.500 g 1.500 g L-Tryptophan 0.600 g 0.600 g 0.600g 0.600g Ethyl cyanosine 0.404g 0.404g 0.404g 0.404g Sodium bisulfite 0.015g 0.015g 0.030g 0.015g Sodium riboflavin phosphate (B2) 2.30mg 2.30mg 2.50mg 2.30mg Pantothenic acid 7.00mg 7.00mg 7.50mg 7.00mg Nicotinamide - 20.00mg - Total 300mL 300mL 300mL 300mL 201021851

成分 實施例1 實施例2 實施例3 比較例1 棕櫚酸視黃醇酯(A) 1650IU 1650IU 2000IU 1650IU 膽鈣化醇(D3) 2.5pg 2.5pg 2.5pg 醋酸生育酚(E) 5.0mg 5.0mg 7.5mg 5.0mg 植物甲萘醌 l.Omg l.Omg l.Omg l.Omg 抗壞血酸 50.0mg 50.0mg lOO.Omg 50.0mg 溶液C 葉酸 0.2mg 0.2mg 0.2mg 0.2mg 生物素(H) 30pg 30pg 50pg 3〇Hg 聚山梨酸酯80 40mg 40mg 40mg 40mg 聚山梨酸酯20 20mg 20mg 20mg 20mg 山梨糖醇 0.288g 0.288g 0.288g 0.288g 碘化鉀 0.083mg 0.083mg 0.083mg - 全量 3mL 3mL 3mL 3mL 三氯化鐵 4.730mg 4.730mg 4.730mg 4.730mg 氣化猛 0.09895mg 0.09895mg 0.09895mg 0.09895mg 硫酸鋅 14.38mg 14.38mg 14.38mg 14.38mg 溶液D 硫酸銅 0.624mg 0.624mg 0.624mg 0.624mg 碘化鉀 - - - 0.083mg 軟骨素硫酸鈉 4.887mg 4.887mg 4.887mg 4.887mg 全量 3mL 3mL 3mL 3mLIngredient Example 1 Example 2 Example 3 Comparative Example 1 Retinyl palmitate (A) 1650 IU 1650 IU 2000 IU 1650 IU Cholecalciferol (D3) 2.5 pg 2.5 pg 2.5 pg Tocopherol acetate (E) 5.0 mg 5.0 mg 7.5 mg 5.0mg Phytomenadione l.Omg l.Omg l.Omg l.Omg Ascorbic acid 50.0mg 50.0mg lOO.Omg 50.0mg Solution C Folic acid 0.2mg 0.2mg 0.2mg 0.2mg Biotin (H) 30pg 30pg 50pg 3〇Hg Polysorbate 80 40mg 40mg 40mg 40mg Polysorbate 20 20mg 20mg 20mg 20mg Sorbitol 0.288g 0.288g 0.288g 0.288g Potassium iodide 0.083mg 0.083mg 0.083mg - Total 3mL 3mL 3mL 3mL Ferric chloride 4.730mg 4.730mg 4.730mg 4.730mg gasification violent 0.09895mg 0.09895mg 0.09895mg 0.09895mg zinc sulfate 14.38mg 14.38mg 14.38mg 14.38mg solution D copper sulfate 0.624mg 0.624mg 0.624mg 0.624mg potassium iodide - - - 0.083mg chondroitin sodium sulfate 4.887mg 4.887 Mg 4.887mg 4.887mg full amount 3mL 3mL 3mL 3mL

[表2] 微量元素之穩 定性 成分 實施例1 比較例1 保存開始時 40°C 75%RH 1 個月 保存開始時 40°C 75%RH1 個月 三氯化鐵 103.5 102.6 101.0 103.1 氯化成錳 100.8 101.2 99.2 99.7 硫酸鋅 100.3 99.0 99.0 99.5 硫酸銅 100.4 100.0 99.4 98.2 碘化鉀 106.5 106.2 99.3 82.0 -28- 201021851 [表3]維生素之穩定性 成分 實S _1 比較例1 保存開始時 40°C 75%RH 1個月 保存開始時 40°C 75%RH 1個月 鹽酸硫胺素(B1) 104.9 101.3 - - 鹽酸吡哆素(B6) 98.1 98.5 - - 菸鹼醯胺 99.4 100.4 - - 氰鈷胺素(B12) 100.0 94.9 - - 核黃素磷酸鈉(B2) 129.7 129.6 - - 泛酸醇 98.7 98.2 - - 棕櫚酸視黃醇酯(A) 111.1 106.5 117.7 120.4 膽鈣化醇(D3) 127.1 134.3 119.1 120.5 醋酸生育酚(E) 104.1 104.7 121.7 121.1 植物甲萘醌(K1) 111.9 111.4 109.1 112.6 抗壞血酸(C) 107.1 106.4 108.1 108.4 葉酸 98.6 97.1 97.3 95.1 生物素 98.9 98.6 92.0 91.7[Table 2] Stabilizing components of trace elements Example 1 Comparative Example 1 40 ° C at the start of storage 75% RH 1 month 40 ° C at the start of storage 75% RH 1 month Ferric chloride 103.5 102.6 101.0 103.1 Chlorination to manganese 100.8 101.2 99.2 99.7 Zinc sulfate 100.3 99.0 99.0 99.5 Copper sulfate 100.4 100.0 99.4 98.2 Potassium iodide 106.5 106.2 99.3 82.0 -28- 201021851 [Table 3] Vitamin stability component S _1 Comparative example 1 Storage start 40 ° C 75% RH 1 At the beginning of the month of storage 40 ° C 75% RH 1 month thiamine hydrochloride (B1) 104.9 101.3 - - pyridoxine hydrochloride (B6) 98.1 98.5 - - Nicotinamide 99.4 100.4 - - Cyanocobalamin (B12 100.0 94.9 - - Riboflavin sodium phosphate (B2) 129.7 129.6 - - Pantothenic acid 98.7 98.2 - - Retinyl palmitate (A) 111.1 106.5 117.7 120.4 Cholecalciferol (D3) 127.1 134.3 119.1 120.5 Tocopherol acetate ( E) 104.1 104.7 121.7 121.1 Menaquinone (K1) 111.9 111.4 109.1 112.6 Ascorbic acid (C) 107.1 106.4 108.1 108.4 Folic acid 98.6 97.1 97.3 95.1 Biotin 98.9 98.6 92.0 91.7

-29- 201021851 [表4]維生素之穩定性（實施例3) 實施例3 成分 保存開始時 40°C 75%RH 1個月 鹽酸硫胺素(B1) 105.4 100.6 鹽酸吡哆素(B6) 98.3 99.2 菸鹼醯胺 102.7 99.8 氰鈷胺素(B12) 100.1 90.1 核黃素磷酸鈉(B2) 110.1 108.7 泛酸醇 104.2 103.8 棕櫚酸視黃醇酯(A) 113.0 111.9 膽鈣化醇(D3) 103.0 106.6 醋酸生育酚(E) 98.5 100.7 植物甲萘醌(K1) 113.8 115.4 抗壞血酸(C) 110.2 109.4 葉酸 99.3 96.6 生物素 100.4 99.1-29- 201021851 [Table 4] Vitamin stability (Example 3) Example 3 Inclusion of ingredients at the beginning of storage 40 ° C 75% RH 1 month thiamine hydrochloride (B1) 105.4 100.6 Pyridoxine hydrochloride (B6) 98.3 99.2 Nicotinamide 102.7 99.8 Cyanocobalamin (B12) 100.1 90.1 Riboflavin sodium phosphate (B2) 110.1 108.7 Pantothenic acid 104.2 103.8 Retinyl palmitate (A) 113.0 111.9 Cholecalciferol (D3) 103.0 106.6 Acetic acid Tocopherol (E) 98.5 100.7 Phytoremediate (K1) 113.8 115.4 Ascorbic acid (C) 110.2 109.4 Folic acid 99.3 96.6 Biotin 100.4 99.1

-30--30-

Claims (1)

201021851 七、申請專利範面： 一種綜合營養輸液劑，其特徵爲：將溶液A、溶 液B、溶液C以及溶液〇收納於經以能連通之隔牆所隔開 之4室容器的各室中，溶液a含有還原糖及維生素B1類 、溶液B含有胺基酸、溶液c含有選自維生素A、維生素 D、維生素E、維生素K：中之至少1種以上的脂溶性維生 素及碘，而溶液D含有銅。 〇 2·—種綜合營養輸液劑，其特徵爲：將溶液A、溶 液B '溶液C以及溶液D收納於經以能連通之隔牆所隔開 之4室容器的各室中，溶液a含有還原糖及維生素B1類 、溶液B含有胺基酸、溶液C含有選自維生素a、維生素 D、維生素E、維生素K中之至少1種以上的脂溶性維生 素及碘’溶液D含有鐵及銅，再者，溶液A及/或溶液B 及/或溶液C及/或溶液D含有電解質，並經加熱滅菌處理 〇 Φ 3.如申請專利範圍第1項或第2項之綜合營養輸液 劑，其中溶液C再含有維生素C且不含維生素B2。 4. 如申請專利範圍第1項或第2項之綜合營養輸液 劑，其中溶液C含有維生素A、維生素D、維生素E、維 生素 K、維生素 C、生物素（biotin )、及葉酸（folic acid)，且不含維生素B2。 5. 如申請專利範圍第1項至第4項之任一項之綜合 營養輸液劑，其中溶液C中的碘的濃度爲0.1 Ommol (毫 莫耳）/公升至〇.25mmol/公升。 -31 - 201021851 6.如申請專利範圍第1項至第5項之任一項之綜合 營養輸液劑，其中溶液A’再含有作爲磷之含磷酸氫二鉀 之電解質，且含有檸檬酸（citric acid)。 7·如申請專利範圍第1項至第6項之任一項之綜合 營養輸液劑，其中溶液A再含有維生素B6、維生素B12 以及薛驗酸（nicotinic acid)類，溶液B再含有維生素 B2以及泛酸（pantothenic acid)類，溶液C再含有維生 素C、維生素Η以及葉酸（folic acid) 。 @ 8. 如申請專利範圍第1項至第6之任一項之綜合營 養輸液劑，其中溶液A再含有維生素B6及維生素B12， 溶液B再含有維生素B2、泛酸類以及菸鹼酸類，而溶液 C再含有維生素C、維生素Η以及葉酸。 9. 如申請專利範圍第1項至第8項之任一項之綜合 營養輸液劑，其中溶液D再含有錳及鋅。 1 0.如申請專利範圍第1項至第9項之任一項之綜合 營養輸液劑，其中電解質係選自鈉、鉀、鎂、鈣、氯（Cl Q )、磷中之至少1種以上。 11. 如申請專利範圍第1項至第10項之任一項之綜 合營養輸液劑，其中維生素Β1類係選自硫胺素（thiamine) 、硫胺素二硫化物（thiamine disulfide)、呋喃硫胺 (fursultiamine)、苯磷硫胺（benfotiamine)以及此等的鹽中 之至少1種以上。 12. 如申請專利範圍第1項至第U項之任一項之綜 合營養輸液劑，其中溶液A的pH爲3至6 ’溶液B、溶 -32- 201021851 液C以及溶液D的pH爲5至8，而混合有溶液A、溶液 B、溶液C以及溶液D之溶液的pH爲4.5至7.5。 1 3 .如申請專利範圍第1項至第1 2項之任一項之綜 合營養輸液劑，其中於混合有溶液A、溶液B、溶液C以 及溶液D時的成分組成中，胺基酸濃度爲25g/公升至 55g/公升。 I4.如申請專利範圍第13項之綜合營養輸液劑’其 _ 中非蛋白卡路里（calorie)與投予氮量的比爲90至1600 Φ -33- 201021851 四、指定代表圖： (一） 、本案指定代表圖為：無 (二） 、本代表圖之元件代表符號簡單說明：無201021851 VII. Patent application: A comprehensive nutrient infusion agent, characterized in that solution A, solution B, solution C and solution are stored in chambers of a 4-chamber container separated by a partition wall that can be connected The solution a contains a reducing sugar and a vitamin B1, the solution B contains an amino acid, and the solution c contains at least one selected from the group consisting of vitamin A, vitamin D, vitamin E, and vitamin K: a fat-soluble vitamin and iodine, and the solution D contains copper. 〇2·-A comprehensive nutrient infusion agent characterized in that: solution A, solution B' solution C and solution D are stored in each chamber of a 4-chamber container separated by a connectable partition wall, and solution a contains a reducing sugar and a vitamin B1, a solution B containing an amino acid, and a solution C containing at least one selected from the group consisting of vitamin A, vitamin D, vitamin E, and vitamin K, and iodine' solution D containing iron and copper. Further, the solution A and/or the solution B and/or the solution C and/or the solution D contain an electrolyte and are subjected to heat sterilization treatment. Φ 3. The comprehensive nutrient infusion solution according to claim 1 or 2, wherein Solution C further contains vitamin C and does not contain vitamin B2. 4. For a comprehensive nutrient infusion solution according to item 1 or 2 of the patent scope, solution C contains vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, biotin, and folic acid. And does not contain vitamin B2. 5. A comprehensive nutrient infusion solution according to any one of claims 1 to 4, wherein the concentration of iodine in solution C is 0.1 Ommol (mole) / liter to 〇. 25 mmol / liter. -31 - 201021851 6. A comprehensive nutrient infusion solution according to any one of claims 1 to 5, wherein the solution A' further contains an electrolyte containing phosphorus dipotassium phosphate as phosphorus and contains citric acid (citric Acid). 7. A comprehensive nutrient infusion solution according to any one of claims 1 to 6, wherein the solution A further contains vitamin B6, vitamin B12 and nicotinic acid, and solution B further contains vitamin B2 and Pantothenic acid, solution C further contains vitamin C, vitamin strontium and folic acid. @ 8. A comprehensive nutrient infusion solution according to any one of claims 1 to 6, wherein solution A further contains vitamin B6 and vitamin B12, and solution B further contains vitamin B2, pantothenic acid and nicotinic acid, and the solution C further contains vitamin C, vitamins and folic acid. 9. A comprehensive nutrient infusion solution according to any one of claims 1 to 8, wherein solution D further comprises manganese and zinc. The comprehensive nutrient infusion solution according to any one of the items 1 to 9, wherein the electrolyte is at least one selected from the group consisting of sodium, potassium, magnesium, calcium, chlorine (Cl Q ) and phosphorus. . 11. A comprehensive nutrient infusion solution according to any one of claims 1 to 10, wherein the vitamin Β1 is selected from the group consisting of thiamine, thiamine disulfide, and furan sulphur. At least one of an amine (fursultiamine), a benfotiamine, and a salt thereof. 12. A comprehensive nutrient infusion solution according to any one of claims 1 to 5, wherein the pH of solution A is 3 to 6 'solution B, solution -32-201021851 liquid C and solution D have a pH of 5 To 8, the pH of the solution in which the solution A, the solution B, the solution C, and the solution D are mixed is 4.5 to 7.5. 1 3. A comprehensive nutrient infusion solution according to any one of claims 1 to 12, wherein the concentration of the amino acid in the composition of the solution A, solution B, solution C and solution D is mixed It is 25g/liter to 55g/liter. I4. For example, the comprehensive nutrient infusion agent of the 13th article of the patent application has a ratio of calorie to nitrogen in the range of 90 to 1600 Φ -33- 201021851 4. Designated representative figure: (1) The representative representative figure of this case is: no (2), the representative symbol of the representative figure is a simple description: no -3- 201021851 五 本案若有化學式時，請揭示最能顢示發明特徵的化學 式：無-3- 201021851 V If there is a chemical formula in this case, please reveal the chemical formula that best shows the characteristics of the invention: none
TW098134787A 2008-10-22 2009-10-14 Total nutrition infusion solution TWI474840B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2008271464 2008-10-22

Publications (2)

Publication Number Publication Date
TW201021851A true TW201021851A (en) 2010-06-16
TWI474840B TWI474840B (en) 2015-03-01

Family

ID=42119341

Family Applications (1)

Application Number Title Priority Date Filing Date
TW098134787A TWI474840B (en) 2008-10-22 2009-10-14 Total nutrition infusion solution

Country Status (3)

Country Link
JP (2) JP5631737B2 (en)
TW (1) TWI474840B (en)
WO (1) WO2010047302A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5568272B2 (en) * 2009-09-29 2014-08-06 テルモ株式会社 Lipid-containing vitamin-containing liquid containing iodine
EP2567700B1 (en) * 2010-05-07 2016-04-20 Ajinomoto Co., Inc. Vitamin-containing nutrition infusion for administration through peripheral vein
JP6235779B2 (en) * 2012-03-28 2017-11-22 株式会社コーセー Folic acid-containing composition and method for stabilizing folic acid
WO2015119183A1 (en) * 2014-02-05 2015-08-13 協和発酵キリン株式会社 Liquid drug containing active vitamin d3 or derivative thereof
JP6771333B2 (en) * 2015-08-07 2020-10-21 テルモ株式会社 Iron-containing injectable preparation
JP6952468B2 (en) * 2017-01-31 2021-10-20 中外製薬株式会社 Aqueous pharmaceutical composition containing a vitamin D compound
JP6925148B2 (en) * 2017-03-28 2021-08-25 テルモ株式会社 Iron-containing infusion
JP7188961B2 (en) * 2018-09-28 2022-12-13 テルモ株式会社 iron-containing infusion

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2990686B2 (en) * 1994-11-17 1999-12-13 田辺製薬株式会社 Total infusion containing water-soluble vitamin B
JP4162306B2 (en) * 1997-09-25 2008-10-08 株式会社大塚製薬工場 Infusion for central venous administration
JP4142282B2 (en) * 2001-11-21 2008-09-03 株式会社大塚製薬工場 Infusion preparations containing trace metals
JP4828111B2 (en) * 2004-10-21 2011-11-30 株式会社大塚製薬工場 General infusion preparation
JP2006124287A (en) * 2004-10-26 2006-05-18 Otsuka Pharmaceut Factory Inc Multiple infusion preparation
JP5048703B2 (en) * 2008-03-18 2012-10-17 株式会社東芝 Image reading apparatus and image reading method

Also Published As

Publication number Publication date
JPWO2010047302A1 (en) 2012-03-22
JP5631737B2 (en) 2014-11-26
JP2014221787A (en) 2014-11-27
JP5828019B2 (en) 2015-12-02
WO2010047302A1 (en) 2010-04-29
TWI474840B (en) 2015-03-01

Similar Documents

Publication Publication Date Title
JP6766112B2 (en) Method for stabilizing vitamin C in nutrient infusion solution for hyperbaric vapor sterilization for peripheral intravenous administration
TW201021851A (en) Total nutrition infusion solution
WO1999039679A1 (en) Vitamin d solution holder and containers for transfusions
EP1632209B1 (en) Aseptic combination preparation
JP4162306B2 (en) Infusion for central venous administration
JP4101418B2 (en) Total nutritional fluid
JP4142282B2 (en) Infusion preparations containing trace metals
JP2004001900A (en) Method for stabilizing vitamins in transfusion for central venous administration
JP3771644B2 (en) Peripheral intravenous infusion
JP2006020657A (en) Trace element-blended infusion preparation
JP4488907B2 (en) Method for producing medical double packaging preparation and medical double packaging preparation
JP4171216B2 (en) Infusion preparations containing sulfur-containing compounds and trace metal elements
JP2006083164A (en) Transfusion product
JP3824716B2 (en) Infusion for central venous administration
JP2004189677A (en) Transfusion preparation
JP2006001945A (en) Vitamin b1-formulated comprehensive transfusion for peripheral intravenous administration
JP2008195737A (en) Infusion preparation containing trace of metal
JP2003055195A (en) Vitamin b1-formulated comprehensive transfusion for peripheral intravenous administration
JPH10203959A (en) Infusion administered into central vein
JP2005035962A (en) Iron-formulated infusion preparation
JP2021024796A (en) Infusion product
TW200914069A (en) Method of producing transfusion for peripheral intravenous administration
JP2005053872A (en) Sugar electrolyte maintenance transfusion solution

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees